ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Paul E. Van Schil
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Schil, P. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Van Schil, P. E.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2003;76:201-202
© 2003 The Society of Thoracic Surgeons

Original article: general thoracic

Invited commentary

Paul E. Van Schil, PhD

Department of Thoracic and Vascular Surgery, University Hospital of Antwerp, B-2650 Edegem (Antwerp), Belgium

e-mail: paul.van.schil@uza.be

The first 20% of the full text of this article appears below.

Current TNM staging is purely anatomical and has its limitations. Even stage I patients do not have an excellent prognosis after complete resection, and approximately 25% will develop distant metastases within 5 years, which are probably already present at the time of resection. In this multicenter study, the prognostic value of cytokeratin-positive (CK+) cells as markers of micrometastases was studied. Bone marrow aspirates obtained immediately before surgical resection and lymph nodes of patients with resected nonsmall cell lung cancer . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2003 by The Society of Thoracic Surgeons.